BOLT vs MTB · rev $7.7M vs P/E 12, $30.99B cap
Bolt Biotherapeutics (BOLT) versus M&T Bank Corporation (MTB) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
M&T Bank Corporation (MTB) is a banks - regional company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
MTB does not have a complete income-statement cache yet.
BOLT currently screens at market cap $11.3M. MTB currently screens at market cap $30.99B and trailing P/E 11.9.
Not investment advice. Open the BOLT and MTB stock pages for the full models.
Not investment advice.